stockportfolio.pro
Arrowhead Pharmaceuticals, Inc. (ARWR)
Healthcare · Biotechnology · NasdaqGS
Arrowhead Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $158,333 | $31.41M | $16.14M | $168.80M | $87.99M | $138.29M | $243.23M | $240.74M | $3.55M | $829.45M |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | $-81.72M | $-34.38M | $-54.45M | $67.97M | $-84.55M | $-140.85M | $-176.06M | $-205.28M | $-599.49M | $-1.63M |
| Net margin | -51614.6% | -109.5% | -337.3% | 40.3% | -96.1% | -101.9% | -72.4% | -85.3% | -16882.4% | -0.2% |
Source: Arrowhead Pharmaceuticals, Inc. SEC filings (10-K). 23 years of history available in the interactive view.
What growth is priced into ARWR stock?
At today's market cap of $10.00B, Arrowhead Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 23.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $156.89M from the FY ending 2025-09-30). For comparison, revenue 56.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 23 years of Arrowhead Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ARWR in your portfolio →
Arrowhead Pharmaceuticals, Inc. financial history by metric
About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals, Inc. — frequently asked questions
What is Arrowhead Pharmaceuticals, Inc.'s revenue?
Arrowhead Pharmaceuticals, Inc. (ARWR) reported revenue of $829.45M for fiscal year 2025, up 23258.2% from the prior year, according to its SEC filings.
Is Arrowhead Pharmaceuticals, Inc. profitable?
No — ARWR reported a net loss of $-1.63M in fiscal 2025.
What is ARWR's P/E ratio?
Arrowhead Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Arrowhead Pharmaceuticals, Inc. growing?
ARWR's revenue grew at roughly 56.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Arrowhead Pharmaceuticals, Inc. have?
As of fiscal year 2025, ARWR carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Arrowhead Pharmaceuticals, Inc.'s market cap?
Arrowhead Pharmaceuticals, Inc. (ARWR) has a market capitalization of about $10.00B, based on the latest data in our nightly-refreshed cache.
When does Arrowhead Pharmaceuticals, Inc.'s fiscal year end?
ARWR's fiscal year ends in September. Its most recent annual filing covers the fiscal year ending 2025-09-30.
What growth is priced into ARWR stock?
At today's market cap of $10.00B, Arrowhead Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 23.6% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $156.89M from the FY ending 2025-09-30). For comparison, revenue 56.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Arrowhead Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 23 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.